Reported about 17 hours ago
BioNTech has reached two settlement agreements, one with the U.S. National Institutes of Health (NIH) and another with the University of Pennsylvania (Penn), regarding royalty payments related to its COVID-19 vaccine. The company will pay $791.5 million to NIH to resolve a default notice and $467 million to Penn, which has dismissed a lawsuit over underpayment of royalties. Partner Pfizer will reimburse part of these payments. The settlements include updated license agreements and do not imply any admission of liability by BioNTech.
Source: YAHOO